Novo Nordisk's inflammation drug ziltivekimab misses the mark in heart disease trial

For more than a decade, a rival theory to the cholesterol-first model of heart disease has been gaining ground in cardiology: that inflammation, independent of cholesterol levels, is quietly driving a large share of heart attacks and strokes. Novo Nordisk had bet heavily on that theory with ziltivekimab, an antibody designed to neutralise interleukin-6, a signalling protein central to the body's inflammatory response. This week the company reported that a major late-stage trial testing the drug in patients with cardiovascular disease and evidence of inflammation did not meet its primary goal of significantly cutting major adverse cardiac events.

The trial enrolled thousands of patients who already had elevated markers of inflammation alongside existing heart disease, a population specifically chosen because they were thought most likely to benefit from an anti-inflammatory approach rather than another cholesterol-lowering drug. Investigators tracked a composite endpoint of cardiovascular death, heart attack and stroke. According to Novo Nordisk's disclosure, the difference between the drug and placebo did not reach statistical significance, meaning the company cannot claim the drug meaningfully reduced those events in this trial population.

The result matters well beyond one company's pipeline. Ziltivekimab was widely seen as the most advanced test yet of the 'inflammation hypothesis' of cardiovascular disease, a theory that traces back to landmark studies showing that a marker of inflammation called CRP predicted heart attacks even in people with normal cholesterol. Those findings reshaped how cardiologists think about risk, but translating the theory into an approved, effective drug has proven far harder than the underlying science suggested it should be.

It is not the first anti-inflammatory approach to stumble in cardiovascular trials. Older anti-inflammatory drugs, repurposed from other diseases, produced mixed results in previous cardiac trials — sometimes showing a modest benefit, sometimes none, and occasionally raising safety concerns around infection risk that come with broadly suppressing the immune system's inflammatory signalling. Ziltivekimab was designed to be more targeted, hitting interleukin-6 specifically rather than blunting inflammation broadly, on the theory that precision would succeed where blunter tools had failed.

Cardiologists not involved in the trial cautioned against reading the result as proof the inflammation hypothesis itself is wrong. Trials can miss their primary endpoint for reasons that have little to do with the underlying biology: the patient population may not have been narrow enough, the trial may have been underpowered to detect a real but modest effect, or the drug's dosing may not have suppressed inflammation enough for long enough. Full data from the trial, expected at a forthcoming cardiology conference, should clarify which of these explanations best fits what happened.

For Novo Nordisk, the setback lands at a moment when the company's identity is increasingly tied to metabolic and cardiometabolic disease through its GLP-1 franchise. Ziltivekimab had been positioned as a potential complement to that portfolio — a drug that could be prescribed alongside weight-loss and diabetes treatments for patients whose cardiovascular risk persists despite good cholesterol and blood sugar control. A negative primary result narrows, though does not necessarily close, the path to that expanded role.

The episode also illustrates a broader pattern in cardiovascular drug development: mechanisms that look compelling in blood tests and smaller studies routinely fail to clear the much higher bar of a large, randomized outcomes trial. Reducing a biomarker is not the same as reducing heart attacks, and regulators generally require the latter, not the former, before approving a drug for this use. Ziltivekimab did lower markers of inflammation in earlier studies, which is precisely why expectations for this larger trial had been high.

Other companies developing inflammation-targeted cardiovascular drugs will be watching closely for the trial's full dataset, since subgroup analyses sometimes reveal that a drug worked well in a specific slice of patients even when the overall population showed no benefit. Regulators and independent researchers tend to treat such subgroup findings with caution, since they can arise by chance in a large dataset, but they can also point toward a narrower, better-defined patient population worth testing in a follow-up trial.

For patients, the near-term practical impact is limited: ziltivekimab was not yet an approved treatment, so no one is being asked to stop a medication. The result instead affects the pipeline of future options for patients whose cardiovascular risk persists despite standard cholesterol-lowering therapy — a group cardiologists say remains large and underserved by currently available drugs.

Novo Nordisk said it would continue to analyse the full trial data before deciding on next steps for the drug, which could include further studies in a more narrowly defined patient population, additional cardiovascular indications, or discontinuation of the cardiovascular program altogether. Either way, the inflammation hypothesis of heart disease — one of the more promising ideas to emerge from cardiology in the past twenty years — has just failed its most rigorous test yet, without being definitively disproven.